Business Wire

Alter Domus Strengthens its Competitive Differentiation with Continued Investments in European Operational Excellence

25.11.2021 10:00:00 EET | Business Wire | Press release

Share

Alter Domus, a leading provider of integrated solutions for the alternative investment industry, is enhancing its European service offering by making substantial investments in its central operations.

The initiative is focused on building additional technology capability, expanding its European footprint, and continuing to recruit exceptional, multilingual talent to support Alter Domus in providing corporate and fund services to investors and managers in private equity, real assets, and debt capital markets.

Launching an Ambitious Digital Agenda

At the core of its €50 million investment is technology. Alter Domus is pursuing an ambitious digital agenda in software development, network and infrastructure, security and systems engineering, and quality assurance.

This complements the rollout of new client-facing technology, CorPro, digitalising investors’ and managers’ traditional workflows to significantly improve access to data and achieve efficiencies across different geographies, funds, and product types.

This in-house technology was enhanced with the acquisition of London-based SaaS platform, Credit-Vision, whose solution for corporate credit investors was vertically integrated into Alter Domus’ technology stack during 2021.

Scaling via European footprint

In addition to expanding its Irish operations in 2021, Alter Domus opened its doors in Lithuania and now benefits from operations centres in Cork, Vilnius, and Malta to house central operations as well as functions including technology and HR. In Ireland and Lithuania alone, Alter Domus has hired more than 200 new employees in 2021. Luxembourg continues to play a critical role in knowledge sharing to Alter Domus’ new operations centres as it remains a leading European centre of excellence.

Exceptional, Specialised Talent

Across Europe, Alter Domus plans to hire an additional 270 technology, accounting, legal, compliance and tax specialists in Luxembourg, Cork, and Vilnius in 2022, to scale across the continent.

This will support Alter Domus in capturing the growing demand for incremental outsourcing as global alternatives investment managers in North America and Asia – who have an estimated $2.5 trillioni in dry powder to deploy – increasingly look to Europe to launch and manage new funds.

Alter Domus has fully deployed a hybrid working model and benefited from a greater appetite amongst exceptional talent to switch functional roles since the beginning of the pandemic. Those alternatives specialists seeking to switch are demanding a more technology-centric role without losing their sector expertise.

Through a proprietary training program, The acADemy, Alter Domus employees are enhancing their technical, professional and leadership skills. 1,800 Alter Domus employees in 13 European locations have already benefited from The acADemy, amounting to over 30,000 hours of training delivery.

Sandra Legrand, Regional Executive for Europe at Alter Domus, said: “In a year when Alter Domus has topped $1 trillion in assets under administration, we have in place the strongest technological capabilities and expanded our talented central operations team to support our clients and the rising complexity of their assets.”

“Our technology investment programme is strengthening our ability to help alternatives investors and managers grapple with a data deluge. Our technology is optimising managers fund and portfolio performance when they’re raising, managing, and deploying funds, and reporting this all back to their end-investors to overcome the intricate web of regulatory and compliance requirements.”

Heather Crowley- Kerr, Head of Central Operations Europe at Alter Domus, said: “Fund administration is a people industry increasingly defined by digital transformation. Whilst we’re automating our processes to serve our clients more efficiently, we’ve more than doubled our workforce in central operations since 2016 to maintain our hybrid operating model which blends human with digital.”

“Through an internal knowledge transfer system, we’ve exported some deep technical knowledge and experience that sits within Luxembourg and Malta to two additional hubs in Cork and Vilnius which now employ over 350 people. In the last year, we’re proud to have trained over 175 employees in the entire alternatives product lifecycle, so we retain our competitive advantage in being the only fund services and asset administration provider solely dedicated to providing superior expertise to private equity, credit, real estate and infrastructure investors and managers.

We look forward to our continued growth within our central operations and to welcoming additional talent to join us on the Alter Domus journey.”

# #

ABOUT ALTER DOMUS

Alter Domus is a leading provider of fund administration, debt capital markets and corporate services for the alternative investment industry. Through vertical integration, dedicated teams provide support and bespoke solutions across entire value chains. By tapping into a talent pool of more than 3,300 employees across 36 offices in 21 jurisdictions, our expertise and cutting-edge technology combine to put clients ahead of the game.

With an established professional focus on private equity, venture capital, real estate, infrastructure, and credit sectors, we offer fund administration, debt capital markets services, corporate services, depositary services, capital administration, transfer pricing, domiciliation and management company services. Our specific experience in the debt capital markets sector allows us to provide specialist solutions such as loan administration, agency services, trade settlement and CLO manager services.

Alter Domus proudly serves 16 of the 20 largest private equity houses, 17 of the 20 largest real estate firms, and 17 of the 20 largest private debt managers in the world. For more information, please visit: www.alterDomus.com.


i Source: Preqin (as at November 2021) North America = $1.778 Tn and APAC = $0.762 Tn of dry powder

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Patrick Gritti
Global Head of Marketing and Communications, Alter Domus
+352 48 18 28 3835
+352 661 112 515
patrick.gritti@alterdomus.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye